Approach to the patient with anaplastic thyroid carcinoma.
about
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsIdentification of a recurrent STRN/ALK fusion in thyroid carcinomasOutcome after intensity modulated radiotherapy for anaplastic thyroid carcinomaMetronomic chemotherapy in anaplastic thyroid carcinoma: a potentially feasible alternative to therapeutic nihilism.Concept and design of a nationwide prospective feasibility/efficacy/safety study of weekly paclitaxel for patients with pathologically confirmed anaplastic thyroid cancer (ATCCJ-PTX-P2).Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.Anaplastic Thyroid Carcinoma, Version 2.2015.The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutationsLenvatinib for Anaplastic Thyroid Cancer.New therapeutic options for advanced forms of thyroid cancer.Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.Significant cytostatic effect of everolimus on a gefitinib-resistant anaplastic thyroid cancer cell line harboring PI3KCA gene mutation.Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma.The Role of Tracheostomy in Anaplastic Thyroid Carcinoma.Airway issues in anaplastic thyroid carcinoma.Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.Guidelines for the management of thyroid cancer
P2860
Q27027491-1A4139F8-5519-4E7E-AFE0-9226268B38CDQ28539208-4341D40F-0FCA-4477-A733-19FFA32C66A9Q35137049-9EA10E3D-B26B-4C27-9BB8-69CD3FF93911Q35636032-94A5863D-7D27-4D85-A586-DDA3B758C70BQ35669034-AA606003-59A5-469C-9D9C-1DE849A59686Q35876617-81DE0754-01DB-463B-B313-56D897BD367AQ36168031-714AFF7A-F8BB-46D9-B993-073F52F041A4Q37179204-F9E8621C-5E4A-459F-A401-3F36B77573A2Q37199459-5E621AE8-21C7-4D5B-8E1F-C42B9EDC68EDQ37672425-A7111B15-5CB2-4B51-8D7A-7948633909F0Q38192680-3CFE8B0B-911E-4BA9-BE4A-965ED6DBDA5DQ38798863-8B61EA8A-CCAB-4ACB-A306-872707A854E4Q38857266-896FC306-808D-408E-B263-B1CBE5E05338Q39041602-539E7AE3-BAE2-47CA-B800-AAFED0C7B7FCQ42680715-5A6EA878-E86E-43F0-8975-B74C8FD34944Q44918252-E50AF188-2C0D-4ADB-907B-4150F0936B15Q45401505-31A03186-AF8F-49BC-AFD0-298525C86333Q46029676-B6B639BC-C34A-42F7-943B-EBD5D603424BQ47247138-E6B59534-5866-4D6A-9874-9504FE827C93Q53644218-97BD4D0A-7724-42B5-B9B7-A4C61A3D441AQ56554243-C17E9C65-EA86-4DD6-A14B-66B108871E3B
P2860
Approach to the patient with anaplastic thyroid carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Approach to the patient with anaplastic thyroid carcinoma.
@ast
Approach to the patient with anaplastic thyroid carcinoma.
@en
type
label
Approach to the patient with anaplastic thyroid carcinoma.
@ast
Approach to the patient with anaplastic thyroid carcinoma.
@en
prefLabel
Approach to the patient with anaplastic thyroid carcinoma.
@ast
Approach to the patient with anaplastic thyroid carcinoma.
@en
P2860
P356
P1476
Approach to the patient with anaplastic thyroid carcinoma.
@en
P2093
Robert C Smallridge
P2860
P304
P356
10.1210/JC.2012-1314
P407
P577
2012-08-01T00:00:00Z